UK medtech CoMind secures $102.5M led by Plural to advance FDA approval of its brain-monitoring system CoMind One and expand its clinical and engineering teams.
CoMind, a London-based medtech company developing non-invasive brain monitoring technology, has raised $102.5 million to advance regulatory approval and commercialization of its first product, CoMind One. The round was led by Plural, with participation from Angelini Ventures, LocalGlobe, Octopus Ventures, Crane Venture Partners, Backed VC, and Entrepreneurs First.
The funding will support FDA regulatory approval, clinical trials, team expansion, and manufacturing partnerships. Plural Partner Taavet Hinrikus will join CoMind’s board alongside Julia Hawkins (LocalGlobe), Michael Tarnoff, and Chair Frank Fischer, joining Founder and CEO James Dacombe.
James Dacombe founded CoMind at age 17 to solve a decades-old dilemma in brain monitoring. “For critically ill patients, clinicians have had to choose between risky, invasive procedures that require drilling into the skull, or unreliable non-invasive tools” he said. “Our technology resolves that compromise for the first time.”
CoMind One is designed to non-invasively measure three key brain parameters, cerebral blood flow, cerebral auto-regulation, and intracranial pressure, simultaneously and continuously at the bedside, something that has never been achieved before.
The company’s breakthrough builds on photonics technology, providing clinicians with real-time access to vital brain data without surgical intervention. CoMind estimates that in the U.S., over three million people suffer traumatic brain injuries annually, yet only five percent receive intracranial pressure monitoring, an invasive procedure that carries a 15% complication rate.
“CoMind’s technology has the potential to dramatically improve how we monitor our brains, providing doctors with better information and safer, more affordable options” said Plural in a statement.
Julia Hawkins, General Partner at LocalGlobe, added: “James is truly a generational founder redefining how the brain is measured and, ultimately, how it’s treated. CoMind is part of a new wave of European science-led startups transforming medicine through engineering.”
The company plans to gain FDA clearance within two years, unlocking access to the U.S. ICU market. CoMind is also developing an AI platform to turn sensor data into predictive insights—detecting complications early and personalizing patient care.